featured
Lifetime Benefits of Comprehensive Disease-Modifying Pharmacological Therapies in Patients With HFrEF
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Estimating Lifetime Benefits of Comprehensive Disease-Modifying Pharmacological Therapies in Patients With Heart Failure With Reduced Ejection Fraction: A Comparative Analysis of Three Randomised Controlled Trials
Lancet 2020 May 21;[EPub Ahead of Print], M Vaduganathan, BL Claggett, PS Jhund, JW Cunningham, J Pedro Ferreira, F Zannad, M Packer, GC Fonarow, JJV McMurray, SD SolomonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.